WA Near Miss Ideas Grants awarded for depression and multiple sclerosis projects
Two Perron Institute researchers are recipients of three $100,000 WA Near-Miss Awards – Ideas Grants awarded by the Cook Government...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
The cause of MS is not known but it is believed that the disease begins with an environmental trigger such as a viral infection, in individuals who have a genetic susceptibility. This results in an autoimmune process confined to the central nervous system (CNS).
Demyelinating Diseases Research, led by Clinical Professor Allan Kermode, is dedicated to investigating the causes of MS and improving the treatment and management of those living with MS and related diseases.
Understanding how the immune-mediated damage in the CNS occurs is the key to understanding MS and to developing new treatments. The Demyelinating Diseases Research Group is involved in several research projects to investigate new forms of pharmacotherapy and engage in international collaborations and is an active member of the IMSGC, ANZGene, MSBase and the Progressive MS Alliance.
We are continuing ongoing research into the clinical profile of different subgroups of patients with demyelinating disease in Western Australia, and the influence of immune-related genes and the role of the antibody in the development of demyelinating diseases.
Investigating the causes of multiple sclerosis and the potential for improved treatment of this distressing neurological disorder is the research focus of the 2022 Perron Institute Aspire Award winner, Dr Marzena Fabis-Pedrini, PhD, pictured here with Steve Arnott, CEO, Perron Institute.
Multiple Sclerosis Clinics provide services for the accurate diagnosis and effective treatment for individuals with multiple sclerosis (MS) and other neuroimmunological disorders of the central nervous system (CNS).
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.